Graves Diseases - Pipeline Review, H1 2018

  • ID: 4576078
  • Report
  • 33 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Apitope International NV
  • Novartis AG
  • Omeros Corp
  • Rodos BioTarget GmbH
  • MORE
Graves Diseases - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Graves Diseases - Pipeline Review, H1 2018, provides an overview of the Graves Diseases (Hormonal Disorders) pipeline landscape.

Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism). Symptoms include anxiety, weight loss, change in menstrual cycles, erectile dysfunction, bulging eyes and irregular heartbeat. Risk factors include family history, age, autoimmune disorders, smoking and pregnancy. Treatment includes anti-thyroid medications, beta blockers and surgery.

Report Highlights:

This latest pipeline guide Graves Diseases - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Graves Diseases (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graves Diseases (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Graves Diseases and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1 and 1 respectively.

Graves Diseases (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Graves Diseases (Hormonal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Graves Diseases (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Graves Diseases (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Graves Diseases (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Graves Diseases (Hormonal Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Graves Diseases (Hormonal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Graves Diseases (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Apitope International NV
  • Novartis AG
  • Omeros Corp
  • Rodos BioTarget GmbH
  • MORE
Introduction

Report Coverage

Graves Diseases - Overview

Graves Diseases - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Graves Diseases - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Graves Diseases - Companies Involved in Therapeutics Development

Apitope International NV

Novartis AG

Omeros Corp

Rodos BioTarget GmbH

Graves Diseases - Drug Profiles

ATXGD-59 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CFZ-533 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

K-170 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein for Graves Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit GPR174 for Immunology, Neurology and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Graves Diseases - Dormant Projects

Graves Diseases - Product Development Milestones

Featured News & Press Releases

Apr 16, 2018: Apitope Announces Positive Results with Novel Treatment for Graves Disease

Oct 26, 2016: Apitope Announces Enrolment of First Patient in Phase I Trial of ATX-GD-59 for the Treatment of Graves Disease

Jun 19, 2014: Apitope Progresses Graves ‘disease Treatment

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Graves Diseases, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Graves Diseases - Pipeline by Apitope International NV, H1 2018

Graves Diseases - Pipeline by Novartis AG, H1 2018

Graves Diseases - Pipeline by Omeros Corp, H1 2018

Graves Diseases - Pipeline by Rodos BioTarget GmbH, H1 2018

Graves Diseases - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Graves Diseases, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Apitope International NV
  • Novartis AG
  • Omeros Corp
  • Rodos BioTarget GmbH
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll